You are here: Industry Insights > ADC Therapeutics

News List

ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma pharmaceutical-business-review
November 24, 2020
ADC Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and ...
ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo pharmaceutical-business-review
July 22, 2020
ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed ...
ADC Therapeutics Appoints Jennifer Creel as CFO contractpharma
April 22, 2020
ADC Therapeutics SA, a clinical-stage oncology-focused biotech focused on the development and commercialization of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors.
ADC Therapeutics, Adagene Ink License Agreement contractpharma
April 26, 2019
ADC Therapeutics, an oncology drug discovery and development company that specializes in antibody drug conjugates (ADCs), and Adagene Inc., an antibody engineering and discovery company ...